Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,023 INR | +0.65% | +0.43% | +26.03% |
Apr. 09 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
Mar. 27 | NATCO Pharma Limited Announces Board Appointments | CI |
Sales 2024 * | 39.19B 470M | Sales 2025 * | 45.13B 541M | Capitalization | 182B 2.18B |
---|---|---|---|---|---|
Net income 2024 * | 13.21B 158M | Net income 2025 * | 15.27B 183M | EV / Sales 2024 * | 4.24 x |
Net cash position 2024 * | 15.67B 188M | Net cash position 2025 * | 31.57B 378M | EV / Sales 2025 * | 3.33 x |
P/E ratio 2024 * |
13.9
x | P/E ratio 2025 * |
12
x | Employees | 3,946 |
Yield 2024 * |
0.99% | Yield 2025 * |
1.11% | Free-Float | 46.76% |
Latest transcript on NATCO Pharma Limited
1 day | +0.64% | ||
1 week | +0.43% | ||
Current month | +0.43% | ||
1 month | +2.27% | ||
3 months | +19.00% | ||
6 months | +36.59% | ||
Current year | +26.03% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 00-07-02 | |
Founder | 78 | 81-09-18 | |
Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 81-09-18 | |
Chief Executive Officer | 46 | 00-07-02 | |
Director/Board Member | 70 | 14-04-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +3.12% | - | |
0.00% | 34 M€ | +3.34% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 1,023 | +0.65% | 89 789 |
24-05-06 | 1,016 | -1.75% | 477,568 |
24-05-03 | 1,034 | +2.27% | 930,313 |
24-05-02 | 1,011 | -0.69% | 340,489 |
24-04-30 | 1,018 | +1.04% | 437,177 |
Delayed Quote NSE India S.E., May 07, 2024 at 12:18 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.03% | 2.22B | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- NATCOPHARM Stock